BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25305747)

  • 21. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
    Curtit E; Pivot X; Henriques J; Paget-Bailly S; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Kerbrat P; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Thomas G; Deleuze JF; Pauporté I; Romieu G; Cox DG
    Breast Cancer Res; 2017 Aug; 19(1):98. PubMed ID: 28830573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication study for reported SNP associations with breast cancer survival.
    Beeghly-Fadiel A; Zheng W; Lu W; Long J; Zheng Y; Cai H; Gu K; Chen Z; Cai Q; Gao YT; Shu XO
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):1019-26. PubMed ID: 22367361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
    Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
    Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer.
    Milovanović J; Todorović-Raković N; Radulovic M
    Cytokine; 2019 Jun; 118():93-98. PubMed ID: 29482885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of triple negative phenotype on breast cancer prognosis.
    Kaplan HG; Malmgren JA
    Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations.
    Jiang L; Deng J; Zhu X; Zheng J; You Y; Li N; Wu H; Lu J; Zhou Y
    Breast Cancer Res; 2012 Jul; 14(4):R105. PubMed ID: 22788972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk allele of SNP rs3803662 and the mRNA level of its closest genes TOX3 and LOC643714 predict adverse outcome for breast cancer patients.
    Gudmundsdottir ET; Barkardottir RB; Arason A; Gunnarsson H; Amundadottir LT; Agnarsson BA; Johannsson OT; Reynisdottir I
    BMC Cancer; 2012 Dec; 12():621. PubMed ID: 23270421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-6 variant is associated with metastasis in breast cancer patients.
    Abana CO; Bingham BS; Cho JH; Graves AJ; Koyama T; Pilarski RT; Chakravarthy AB; Xia F
    PLoS One; 2017; 12(7):e0181725. PubMed ID: 28732081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Association of single nucleotide polymorphisms in PAI-1 with breast cancer susceptibility and prognosis].
    Chen YL; Jia YM; Xie YT; Li Y; Fang WG; Tian XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):533-9. PubMed ID: 27510778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
    Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
    Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
    Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
    Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.
    Tapper W; Hammond V; Gerty S; Ennis S; Simmonds P; Collins A; ; Eccles D
    Breast Cancer Res; 2008; 10(6):R108. PubMed ID: 19094228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of insulin receptor substrate 1 and estrogen receptor as prognostic factor on breast cancer patient.
    Kim HG; Woo SU; Kim HY; Son GS; Lee JB; Bae JW; Woo OH; Yang DS; Seo JH; Kim AR
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S494-S498. PubMed ID: 29970713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.
    Khan S; Fagerholm R; Rafiq S; Tapper W; Aittomäki K; Liu J; Blomqvist C; Eccles D; Nevanlinna H
    Clin Cancer Res; 2015 Sep; 21(18):4086-4096. PubMed ID: 25964295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
    Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
    Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.